MEGF6

Across TCGA pan-cancer cohorts, MEGF6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MEGF6 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MEGF6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MEGF6 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LSCC, CCRCC, and LUAD are the cancer types where MEGF6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.534	0.923	.001	32	view →
CCRCC	DFS	Median	II,III,IV	0.064	0.972	.006	25	view →
LUAD	DFS	Tertile	All	1.000	0.636	.008	9	view →
UCEC	OS	Median	III,IV	0.566	1.000	.036	4	view →
HNSC	DFS	Median	IV	0.889	0.407	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MEGF6–LSCC (DFS)

Open the LSCC breakdown →